Lead optimization studies of cinnamic amide EP2 antagonists - Test2 - elhamkhani - TriplyDB

Lead optimization studies of cinnamic amide EP2 antagonists

Lead optimization studies of cinnamic amide EP2 antagonists

http://www.wikidata.org/entity/Q33654575

about

Development of second generation EP2 antagonists with high selectivity Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus EP2 Receptor Signaling Regulates Microglia Death.Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Anti-Inflammatory Small Molecules To Treat Seizures and Epilepsy: From Bench to Bedside Defining the therapeutic time window for suppressing the inflammatory prostaglandin E2 signaling after status epilepticus.Cinnamamide Derivatives for Central and Peripheral Nervous System Disorders--A Review of Structure-Activity Relationships.Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype.TBHP-mediated highly efficient dehydrogenative cross-oxidative coupling of methylarenes with acetanilides.Inhibition of the prostaglandin E2 receptor EP2 prevents status epilepticus-induced deficits in the novel object recognition task in rats.Palladium-catalysed direct C-2 methylation of indoles.Sinapic Acid Derivatives as Potential Anti-Inflammatory Agents: Synthesis and Biological Evaluation.

P2860

Q33939410-E411A936-80F9-4707-8CC3-1570DC3C529D Q35534894-1CAD4540-FC4D-452D-A1CE-817B338C7498 Q35745955-19A52E04-9375-41D9-A3DF-17904552C819 Q36833728-46FF11FA-4239-4B77-80F8-9D3FDDDDD7E0 Q37340703-4AF55052-5BCF-4B86-8D6D-0DA85778791F Q37350938-637195E0-D5D2-4FAF-A148-59C210DE7D9B Q38530238-534D1087-9AC6-42B7-A4BD-C27AA7701CAD Q41533962-2EC829DB-B67B-41A2-B1CA-65122E9DAFFA Q42330217-33D55348-14CA-45B1-BBC8-C9554B0E9D11 Q42581871-18226328-B643-46C2-B77D-0E7DD2A8E27B Q51245689-2462806B-DA2A-49DA-B483-46311ECF5E13 Q55239689-DF4C4A8A-BE2F-459D-9E26-E63C486EC26E

P2860

Lead optimization studies of cinnamic amide EP2 antagonists

http://www.wikidata.org/entity/Q33654575

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Lead optimization studies of cinnamic amide EP2 antagonists

@ast

Lead optimization studies of cinnamic amide EP2 antagonists

@en

type

label

Lead optimization studies of cinnamic amide EP2 antagonists

@ast

Lead optimization studies of cinnamic amide EP2 antagonists

@en

prefLabel

Lead optimization studies of cinnamic amide EP2 antagonists

@ast

Lead optimization studies of cinnamic amide EP2 antagonists

@en

P1433

Q33654575-63F6733B-3A17-47C3-957E-A9F52779ABD2

P1476

Q33654575-2BCCDDDF-2F76-4CDC-95A6-B15C2F5EAD94

P2093

Q33654575-731D77D2-DC7F-492F-910C-08802B9CA590

Q33654575-8751C5AC-30BF-48FF-B20F-90CB9F2D0546

P2860

Q33654575-0159B24D-02E8-4410-8022-7F4B258774A2

Q33654575-06BD3C38-89C4-4FBC-88FB-4F8D52BDCE44

Q33654575-09E3DEFF-36C1-4574-9720-8B35C99AD07E

Q33654575-0E56A686-1566-48F1-BB4B-3BB479AFEC31

Q33654575-11170ECE-4843-408F-92D5-DD8EBF8475D0

Q33654575-15BC2D79-EC0A-4FAF-B084-D8AC47D82DEA

Q33654575-217EEE1D-AF00-4B96-AC72-9BC236F34642

Q33654575-26DA5358-B333-4CB4-A8BE-7875375CF6C0

Q33654575-281A6AFA-3821-45C4-9DAA-D291461E01CD

Q33654575-2BFB3C59-A6DD-4981-9FAD-10D884934955

P304

Q33654575-0092D0B4-254F-4FC3-8504-D8F7A9B63968

P31

Q33654575-AA1A5EDD-DBE4-4F67-A165-7496CFC2B1C4

P356

Q33654575-EA0C1907-FC7C-4982-9644-F93F1E549713

P407

Q33654575-BF8E85E6-41DB-4E4B-8F21-613355EF52D3

P433

Q33654575-F5068927-3C52-4E37-93D7-9BC822B568B7

P478

Q33654575-C17DDA06-EA99-48C9-A19C-CFFFB59BCC36

P50

Q33654575-63BA71C6-431D-4ADD-998A-B35FFF4DDF44

Q33654575-9C2A352C-BAA6-4F31-AC39-D95EE77AD43B

P577

Q33654575-03798992-B3DB-4ACA-9596-3B989F971860

P5875

Q33654575-BB5C516A-89FF-456E-A15D-FFC76A0CF37C

P698

Q33654575-F3EC7A73-D189-4C39-A69A-A638F4AE0E6F

P932

Q33654575-0C2D67AA-FB43-42D8-A505-567ED53993A3

P356

P1433

Journal of Medicinal Chemistry

P1476

Lead optimization studies of cinnamic amide EP2 antagonists

@en

P2093

Myung-Soon Yang

http://www.w3.org/2001/XMLSchema#string

Thota Ganesh

http://www.w3.org/2001/XMLSchema#string

P2860

Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP

The blood-brain barrier: bottleneck in brain drug development

Inflammation and Alzheimer's disease

Prostanoid receptors: structures, properties, and functions

A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates.

Selective inhibition of prostaglandin E2 receptors EP2 and EP4 induces apoptosis of human endometriotic cells through suppression of ERK1/2, AKT, NFkappaB, and beta-catenin pathways and activation of intrinsic apoptotic mechanisms.

Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection

Prostanoid receptor EP2 as a therapeutic target

Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor.

Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.

P304

4173-4184

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM5000672

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P50

Jianxiong Jiang

Raymond Dingledine

P577

2014-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261953473

http://www.w3.org/2001/XMLSchema#string

P698

24773616

http://www.w3.org/2001/XMLSchema#string

P932

4032197

http://www.w3.org/2001/XMLSchema#string